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Abstract Idiopathic pulmonary fibrosis (IPF) isknown as anindependentrisk factor forlungcancer.Because Epstein^
Barr virus (EBV) maybe involved in the genesis of IPF aswell as certainmalignancies, we investigatedwhether EBV con-
tributes to the increased incidence of lung cancer in IPF.The formalin-fixed and paraffin-embedded lung sections were
prepared from 22 lungcancerpatientswith IPFand 22 lungcancerpatientswithout IPF.All ofthe IPF patientspathologi-
cally showedusualinterstitialpneumonia. In situhybridization for EBV-encoded smallnon-polyadenylated RNAs failed to
show positive signals in the cancer tissues of either IPF or non-IPF patients.This study did not provide evidence for an
etiologic role of EBVinthe developmentof lungcancer in IPF.
r 2002 Elsevier Science Ltd.Allrights reserved.
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Idiopathic pulmonary ¢brosis (IPF) is a chronic intersti-
tial lung diseasewith a poor prognosis and survival after
diagnosis averages 4^5 years (1,2). Although the etiology
of IPF remains unclear, recent publications have sug-
gested that Epstein^Barr virus (EBV) may be involved
in the development of this disease (3^5).
The close association of EBVwith certainmalignancies
has been documented. EBV is implicated in the develop-
ment of lymphoid malignancies, including Burkitt’s lym-
phoma, immunode¢ciency-related lymphoproliferative
disorders, T/NK cell lymphoma, lymphomatoid granulo-
matosis and Hodgkin’s disease (6,7). EBV is also asso-
ciated with the genesis of lymphoepithelioma-like
carcinoma (LELC), a special entity of epithelial neoplasm
thatpresents as undi¡erentiated carcinomawithmarked
lymphocytic in¢ltration and a¡ects various organs such
as the nasopharynx, stomach, salivary gland, thymus,
and lung (8^12).Received 26 October 2001, accepted in revised form 24 June 2002.
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for lung cancer (13,14), but the mechanism underlying
the increased incidence of lung cancer in IPF remains un-
clear. In this study, we investigated whether EBV contri-
butes to thegenesis of lung cancer in IPF byutilizingin situ
hybridization for EBV-encoded small non-polyadenylated
RNAs (EBERs).
PATIENTSANDMETHODS
The subjects included 22 primary lung cancer patients
with IPF who underwent lobectomyor pneumonectomy
between1994 and1997.They were allmenwith a history
of smoking and the average age was 68.5 years. IPF was
diagnosed on clinical and radiological grounds, as well as
being con¢rmed pathologically in resected lung speci-
mens. As a control, 22 lung cancer patients without IPF
who were all smokers (18 men and four women with a
mean age of 67.5 years) were also studied.
Tissue specimenswere ¢xedwith10%neutralbu¡ered
formalin and embedded in para⁄n. In situ hybridization
was carried out on 5-mm sections utilizing a £uores-
cein-conjugatedpeptide nucleic acid (PNA) probe (Dako
Japan, Tokyo) that was complementary to a portion
FIG. 1. EBERsdetectionincanceroustissues frompatientswith
gastric cancer. (a) Negative control; (b) Positive control.
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hybridization detection kit (Dako Japan). Brie£y, the sec-
tions were mounted on 3-aminopropyltriethoxysilane-
coated slides, depara⁄nized, and rehydrated. After pre-
digestion with proteinase K, hybridization was per-
formed at 551C for 90min, with a £uorescein-
conjugated PNA probe. Fluorescein-conjugated random
PNA probes and £uorescein-conjugated PNA probe
directed against glyceraldehyde 3-phosphate dehydro-
genase were also used as controls. The slides were
then washed with stringent wash solution, and reacted
with an alkaline phosphatase-conjugated antibody to
£uorescein at room temperature for 30min. After
washing, the reaction products were developed using
the nitroblue tetrazolium chloride/5-bromo-4-chloro-
3-indolylphosphate system. A positive reaction was
characterized by dark blue coloration within the
nucleus. In each hybridization experiment, a known
EBV-positive gastric carcinomawas included as a positive
control, which always showed positive staining for
EBERs (Fig.1). At least ¢ve sections were investigated in
each case.
RESULTS
Table1summarizes the results.Microscopic examination
in IPF patients revealed that ¢ve had adenocarcinoma
and 17 had squamous cell carcinoma. All of the IPF pa-
tients pathologically showed usual interstitial pneumo-
nia. In contrast, the non-IPF patients consisted of11with
adenocarcinoma, nine with squamous cell carcinoma,
and with small cell carcinoma, respectively. There were
no LELC cases in both groups. In situ hybridization
showed no positive signals for EBERs in the cancer tis-
sues of either IPF or non-IPF patients.
DISCUSSION
EBV is a ubiquitous human herpes virus and most Japa-
nese people are seropositive after 20 years old.
Although association of EBVwith development of sev-
eral types of malignancies has been strongly suggested,
mechanisms leading to the phenomenon remain largely
unknown (6^12). In non-malignant diseases, serological
and immunohistochemical study as well as DNA assay
have suggested that IPF and collagen diseases including
rheumatoid arthritis, Sjogren syndrome and systemic lu-
pus erythematosus may be EBV-associated conditions
(3^5,15^17).
EBERs are small EBV-encoded non-polyadenylated
RNA transcripts that are extremely abundant (105^7 per
infected cell) (18), and the in situ hybridization for EBERs
has been proven to be highly sensitive for the detection
of EBV-infected cells in the tissues of EBV-associated
tumors (6,10^12,19). Regarding lung cancer, strongexpression of EBERshasbeenreported in LELC, suggest-
ing an association of EBV with this tumor (8^12)
(Table 2).However, the role of EBVremains controversial
in other histological types of lung cancer (Table 2).
For example, Wong et al. (12) and Conway et al. (19)
found no EBERs expression in adenocarcinoma, squa-
mous cell carcinoma, and small cell carcinoma, whereas
Kasai et al. (11) and Chen et al. (10) reported positive
staining for EBERs in 5% (2/41cases) of adenocarcinomas
and 14% (6/43 cases) of squamous cell carcinomas,
respectively.
The present study collectively assessed16 adenocarci-
nomas, 26 squamous cell carcinomas and two small cell
carcinomas, and indicated that EBERswerenot detected
in the lung cancer tissues from both IPF and non-IPF pa-
tients, showingno evidence for an etiologic role of EBVin
the development of lung cancer in IPF. Accordingly, the
increased incidence of lung cancer in IPF may need to be
explained by mechanism(s) other than EBV. In this re-
gard, although a previous report has suggested
that chronic DNA damage and repair in IPF may lead to
mutation of p53 gene, a tumor suppressor gene, and
tumorigenesis in the disease (20), this issue remains to
be further investigated.
TABLE 1. Pathological and in situhybridization ¢ndings
Histological type IPF patients Non-IPF patients
Numberof
patients
Numberof
EBERs-positive patients
Number
of patients
Number
of EBERs-positive
patients
Squamous cell carcinoma 17 0 9 0
Adenocarcinoma 5 0 11 0
Small cell carcinoma 0 0 2 0
Total 22 0 22 0
TABLE 2. Studies of EBERs expression in lungcancer
Frequencyof EBERs-positive cases
Author Adenoca. Squamous cell ca. Small cell ca. Large cell ca. LELC
Kasai et al. (7),1994 2/41 0/20 0/14 0/2 ND
Wong et al. (8) 1995 0/98 0/44 ND 0/12 9/9
Conway et al. (12),1996 0/80 ND ND N.D. ND
Su and Chen (6),1998 0/67 6/43 ND 0/12 5/5
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